In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring ...

BioArctic AB (publ) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

Courtesy of Photo by Matt Payne of Durango, Colorado|Getty Images Many critics, travelers and locals agree that of all of Portland's parks (and they are numerous), Washington Park is perhaps the ...

These data show that 46% of patients improved or had no decline, and 33% showed improvement from baseline on the CDR-SB, with similar results for ADAS-Cog14 and on the ADCS MCI-ADL scales.

Objective Mass casualty incidents (MCIs) come unannounced, mandating the immediate shift from the daily routine to crisis mode through the implementation of an MCI response plan (plan). On August 4, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On the ADCS MCI-ADL, 51% of patients showed improvement or no decline and 48% showed improvement. These results – from no tau/low tau population and low amyloid populations – suggest that ...

Table 1. Description of various cognitive domains and associated effects of age in adulthood. – Prospective memory Remembering to perform intended actions at the appropriate moment in the ...